Alimera Sciences Inc (NASDAQ:ALIM)

2.62
Delayed Data
As of 1:18pm ET
 -0.02 / -0.76%
Today’s Change
2.03
Today|||52-Week Range
7.92
-3.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$18.9M

Company Description

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Contact Information

Alimera Sciences, Inc.
6310 Town Square
Alpharetta Georgia 30005
P:(678) 990-5740
Investor Relations:

Employees

Shareholders

Mutual fund holders4.56%
Other institutional25.83%
Individual stakeholders15.61%

Top Executives

Richard S. EiswirthPresident, Chief Executive Officer & Director
Philip John AshmanCOO & SVP-Commercial Operations Europe
Russell L. SkibstedChief Financial Officer & Senior Vice President
Christopher S. VisickSecretary, Vice President & General Counsel
David DyerChief Retina Specialist